Clinical trials
Chronic Periodontitis trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Unknown status | 4 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Sao Paulo | 7 |
| University of Campinas, Brazil | 4 |
| Universidade Estadual Paulista Júlio de Mesquita Filho | 3 |
| Universidade Federal Fluminense | 2 |
| University of Guarulhos | 2 |
| Belén Retamal-Valdes | 1 |
| Centro Universitario de Lavras | 1 |
| Eduardo Aleixo Figueira | 1 |
| Federal University of Minas Gerais | 1 |
| State University of Maringá | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chronic Periodontitis | 24 |
| Periodontal Diseases | 10 |
| Periodontitis | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Diabetes Mellitus | 3 |
| Acquired Immunodeficiency Syndrome | 1 |
| Alveolar Bone Loss | 1 |
| Atherosclerosis | 1 |
| Periodontal Pocket | 1 |
Trials
Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.